Studies of the mechanism of the anticonvulsant effect of delta-sleep-inducing peptide in conditions of increased oxygen tension.
Mendzheritskii. A M AM; Lysenko. A V AV; Uskova. N I NI; Sametskii. E A EA
Key Findings
- The optimal dose in rats was 12 µg per 100 g body weight given intraperitoneally.
- At this dose, DSIP delayed the start of generalized convulsions by 2‑2.5 times under hyperbaric oxygen (0.7 MPa).
- DSIP promoted normalization of the sleep‑walking cycle within 24 hours after hyperbaric oxygen exposure, likely by balancing excitatory and inhibitory amino‑acid neurotransmitters.
Practical Outcomes
- For DIY biohackers, the study suggests DSIP might have neuro‑protective properties under extreme oxidative stress, but the experimental conditions (high‑pressure oxygen, animal injection) are far from everyday human use. No clear dosing or administration protocol for people can be drawn, so the finding is more of a curiosity that warrants further human‑focused research before any practical application.
Summary
In rats, a specific dose of the peptide delta‑sleep‑inducing peptide (DSIP) helped protect the brain when the animals were exposed to very high oxygen levels. The peptide slowed down seizure onset and helped the animals return to normal sleep patterns within a day.
Abstract
Studies of the protective actions of three doses of delta-sleep-inducing peptide (DSIP) given at different times before barochamber compression of animals to an oxygen tension of 0.7 MPa showed that the optimum DSIP dose is 12 micrograms/100 g. Intraperitoneal administration of this dose of DSIP delayed the onset of generalized convulsive activity by a factor of 2-2.5 in animals exposed to an oxygen tension of 0.7 MPa and promoted normalization of the sleep-walking cycle within 24 h after exposure to hyperbaric oxygen (HBO), by creating an optimal balance between excitatory and inhibitory amino acid neuromediators.
Study Information
pubmed
1997
10.1007/bf02461934